220 related articles for article (PubMed ID: 15980026)
1. Antibiotic treatment of community acquired pneumonia in well-nourished young Nigerian children.
Ajayi MT; Oladokun RA; Falade AG
J Trop Pediatr; 2005 Oct; 51(5):319-20. PubMed ID: 15980026
[No Abstract] [Full Text] [Related]
2. [Community acquired pneumonia].
Marrie TJ
Praxis (Bern 1994); 2001 May; 90(21):935-40. PubMed ID: 11512537
[No Abstract] [Full Text] [Related]
3. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children.
Muszynski JA; Knatz NL; Sargel CL; Fernandez SA; Marquardt DJ; Hall MW
Pediatr Infect Dis J; 2011 Apr; 30(4):295-301. PubMed ID: 21030885
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of linezolid and imipenem association in the treatment of severe community-acquired pneumonia in children: two case reports.
Godon N; Denizot S; Podevin G; Caillon J; Potel G; Christophe Roze J; Gras-Le Guen C
Scand J Infect Dis; 2006; 38(5):381-3. PubMed ID: 16709543
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for the management of community-acquired pneumonia in children.
Lee PI; Chiu CH; Chen PY; Lee CY; Lin TY;
Acta Paediatr Taiwan; 2007; 48(4):167-80. PubMed ID: 18265536
[No Abstract] [Full Text] [Related]
6. Timely antibiotic therapy for community-acquired pneumonia.
Mansel JK
J Miss State Med Assoc; 2004 May; 45(5):159. PubMed ID: 15162706
[No Abstract] [Full Text] [Related]
7. Culture versus polymerase chain reaction for the etiologic diagnosis of community-acquired pneumonia in antibiotic-pretreated pediatric patients.
Deng J; Zheng Y; Zhao R; Wright PF; Stratton CW; Tang YW
Pediatr Infect Dis J; 2009 Jan; 28(1):53-5. PubMed ID: 19034066
[TBL] [Abstract][Full Text] [Related]
8. Short-course treatment of community-acquired pneumonia.
Mandell LA; File TM
Clin Infect Dis; 2003 Sep; 37(6):761-3. PubMed ID: 12955635
[No Abstract] [Full Text] [Related]
9. Guidelines for treatment of community-acquired pneumonia.
Kim MK; Nightingale C; Quintiliani R
Conn Med; 2001 Aug; 65(8):473-5. PubMed ID: 11550446
[No Abstract] [Full Text] [Related]
10. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
Starodubtseva OI; Vakhrushev IaM
Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
[TBL] [Abstract][Full Text] [Related]
11. Drugs of choice for community-acquired bacterial pneumonia.
Med Lett Drugs Ther; 2007 Jul; 49(1266):62-4. PubMed ID: 17652999
[No Abstract] [Full Text] [Related]
12. Doxycycline for community-acquired pneumonia.
Cunha BA
Clin Infect Dis; 2003 Sep; 37(6):870. PubMed ID: 12955665
[No Abstract] [Full Text] [Related]
13. [Uncomplicated community-acquired pneumonia. Under control in 3 treatment days].
MMW Fortschr Med; 2003 Jan; 145(3-4):58. PubMed ID: 12619240
[No Abstract] [Full Text] [Related]
14. [Antibiotic therapy of bronchial infections. 2: Community acquired and nosocomial pneumonias].
Buchenroth M
MMW Fortschr Med; 1999 Dec; 141(49-50):48-50. PubMed ID: 10726149
[No Abstract] [Full Text] [Related]
15. Community acquired pneumonia.
Loeb M
Clin Evid; 2003 Dec; (10):1724-37. PubMed ID: 15555173
[No Abstract] [Full Text] [Related]
16. Community-acquired pneumonia.
Stein RT; Marostica PJ
Paediatr Respir Rev; 2006; 7 Suppl 1():S136-7. PubMed ID: 16798540
[TBL] [Abstract][Full Text] [Related]
17. Treatment of community-acquired pneumonia Down Under versus the United States: is it really that different?
Mandell L
Clin Infect Dis; 2008 May; 46(10):1522-4. PubMed ID: 18419485
[No Abstract] [Full Text] [Related]
18. [Recommendations for therapy of community-acquired pneumonia. German Society of Pneumology].
Schaberg T; Dalhoff K; Ewig S; Lorenz J; Wilkens H
Pneumologie; 1998 Aug; 52(8):450-62. PubMed ID: 9774872
[No Abstract] [Full Text] [Related]
19. Clinical end points of therapy for patients with mild community-acquired pneumonia.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S140-4. PubMed ID: 18986280
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Tillotson GS; Echols RM
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
